Site Search

Share

X

Search Results

Connecticut House Votes to Improve Access to Biomarker Testing

HARTFORD – May 9, 2025 – Yesterday, the Connecticut House voted in unanimous support of legislation that would ensure biomarker testing is covered by state regulated insurance plans, including Medicaid, when supported by scientific and medical evidence. The goal of the ... a statement from Bryte Johnson, government relations director for the American Cancer Society Cancer Action Network (ACS CAN) in Connecticut: “Biomarker testing is essential to high-quality, personalized care for many conditions and can be a real gamechanger for many patients, but ...

The Landscape of Biomarker Testing Coverage in the U.S.

Biomarker testing is becoming increasingly important for cancer care because it connects the right patient, to the right treatment, at the right time, however insurance coverage of testing varies widely. This study, that examines administrative claims data to understand the premium impact of expanding biomarker testing coverage in four markets: commercial self-insured large group, small group, individual, and Medicaid, found a small potential ...

Sign to Expand Access to Biomarker Testing in Maine

Add your voice to our petition to support legislation that would expand health insurance coverage of biomarker testing in Maine. 0 Sign to Expand Access to Biomarker Testing in Maine ...

Sign to Expand Access to Biomarker Testing in Vermont

Add your voice to our petition to support legislation that would expand health insurance coverage of biomarker testing in Vermont. 0 Sign to Expand Access to Biomarker Testing in Vermont ...

Rhode Island Senate Votes to Remove Barriers to Biomarker Testing

PROVIDENCE –Today, the Rhode Island Senate passed legislation that would ensure biomarker testing is covered by more insurance plans, including Medicaid, when patients need it. Dubbed ‘the right treatment, to the right patient, at the right time,’ precision medicine has played a critical role in improving cancer outcomes – biomarker testing being one of the ways we can achieve these outcomes by allowing doctors to understand and target unique markers in a patient’s ...

Biomarker Testing Bill Passes Senate Committee, Advances to Senate Floor

Earlier this morning, House Bill 1754 was voted out of the Senate Banking & Insurance Committee. This legislation, which aims to ensure that biomarker testing is covered by Medicaid and all other state-regulated insurance plans when patients need it, now advances to the Senate floor for consideration. Biomarker testing is a precision medicine tool that utilizes information from patients’ disease cells to determine the right treatment at the ...

Senate & House Vote Unanimously to Increase Access to Biomarker Testing

HARTFORD – May 21, 2025 – Earlier today, the Connecticut Senate voted in unanimous support of legislation that would ensure biomarker testing is covered by state regulated insurance plans, including Medicaid, when supported by scientific and medical evidence. This vote comes on ... (ACS CAN) in Connecticut: “We are thrilled to see back-to-back unanimous votes from the Senate and House in support of increased access to biomarker testing. Expanding access to this form of precision medicine will help more people in Connecticut get the right treatment at the right ...

Sign to Expand Access to Biomarker Testing in New Hampshire

Add your voice to our petition to support legislation that would expand health insurance coverage of biomarker testing in New Hampshire. 0 Sign to Expand Access to Biomarker Testing in New Hampshire ...

Gov. Moore Approves Legislation to Expand Access to Biomarker Testing

... Gov. Wes Moore will be signing HB 1217 / SB 805—among many other bills—into law. This legislation will increase insurance coverage for biomarker testing, making this form of precision medicine available to more Marylanders. The signing ceremony will take place today at 12:00pm in the State ... champions who saw HB 1217 / SB 805 to the finish line. For more information on precision medicine, cancer biomarkers, current barriers to biomarker testing and ACS CAN’s policy recommendations, visit:  www.fightcancer.org/biomarkers . ###  About ACS CAN The American Cancer Society ...

Pharmacogenomic (PGx) Testing: Tests Guide Appropriate Drug Selection and Dosing

Pharmacogenomic (PGx) testing (also known as pharmacogenomic biomarker testing) is a component of precision medicine that involves examining a patient’s inherited genes to detect variations that may impact the way a ... treatment given to patients with the same disease can produce different responses based on each person's inherited genes. Pharmacogenomic (PGx) Testing: Tests Guide Appropriate Drug Selection and Dosing ...

Type

Priority Issue

State

Policy Issue

Judicial Advocacy